UK drug watchdog NCIE has issued draft guidance rejecting the routine use of Sanofi’s Dupixent (dupilumab) for the treatment of moderate-to-severe atopic dermatitis on the NHS in adults when systemic therapy is suitable, citing, as usual, cost-effectiveness concerns.
Reageer